Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial.

BACKGROUND: The American Academy of Pediatrics recommends a permissive hypoxaemic target for an oxygen saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommendations for targets in children with lower respiratory tract infections. No evidence exists to support this threshold. We aimed to assess whether the 90% or higher target for management of oxygen supplementation was equivalent to a normoxic 94% or higher target for infants admitted to hospital with viral bronchiolitis. METHODS: We did a parallel-group, randomised, controlled, equivalence trial of infants aged 6 weeks to 12 months of age with physician-diagnosed bronchiolitis newly admitted into eight paediatric hospital units in the UK (the Bronchiolitis of Infancy Discharge Study [BIDS]). A central computer randomly allocated (1:1) infants, in varying length blocks of four and six and without stratification, to be clipped to standard oximeters (patients treated with oxygen if pulse oxygen saturation [SpO2] <94%) or modified oximeters (displayed a measured value of 90% as 94%, therefore oxygen not given until SpO2 <90%). All parents, clinical staff, and outcome assessors were masked to allocation. The primary outcome was time to resolution of cough (prespecified equivalence limits of plus or minus 2 days) in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN28405428. FINDINGS: Between Oct 3, and March 30, 2012, and Oct 1, and March 29, 2013, we randomly assigned 308 infants to standard oximeters and 307 infants to modified oximeters. Cough resolved by 15·0 days (median) in both groups (95% CI for difference -1 to 2) and so oxygen thresholds were equivalent. We recorded 35 serious adverse events in 32 infants in the standard care group and 25 serious adverse events in 24 infants in the modified care group. In the standard care group, eight infants transferred to a high-dependency unit, 23 were readmitted, and one had a prolonged hospital stay. In the modified care group, 12 infants were transferred to a high-dependency unit and 12 were readmitted to hospital. Recorded adverse events did not differ significantly. INTERPRETATION: Management of infants with bronchiolitis to an oxygen saturation target of 90% or higher is as safe and clinically effective as one of 94% or higher. Future research should assess the benefits and risks of different oxygen saturation targets in acute respiratory infection in older children, particularly in developing nations where resources are scarce. FUNDING: National Institute for Health Research, Health Technology Assessment programme.

Isoprene levels in the exhaled breath of 200 healthy pupils within the age range 7-18 years studied using SIFT-MS.

The published results of breath isoprene studies, to date largely involving adults, are briefly reviewed with special attention given to the work done on this topic during the last 10 years using selected ion flow tube mass spectrometry, SIFT-MS. Then the new data recently obtained on isoprene levels in the exhaled breath of some 200 healthy children and young adults (pupils) with ages ranging from 7 to 18 years measured using SIFT-MS are presented in detail. A concentration distribution has been constructed from the data obtained and compared to that for healthy adults also obtained from SIFT-MS data. Although there is overlap between the two distributions, which are close to log normal in both cases, the median level for the young cohort is much lower at 37 parts-per-billion, pbb, geometric standard deviation, GSD, 2.5, compared to that for the adult cohort of 106 ppb with a GSD of 1.65. Further to this, there is a clear increase in the mean breath isoprene concentration with age for the young cohort with a doubling of the level about every 5-6 years until it reaches the age-invariant mean level of that for adult cohort. Should this trend be extrapolated downwards in age it would indicate a near-zero breath isoprene in the newborn that was indicated by a previous study. Indeed, in the present study isoprene was not detected on the breath of two young children. The results reveal mean breath isoprene levels (±SD) for pupils within the given age ranges as 7-10 years (28 ± 24 ppb), 10-13 years (40 ± 21 ppb), 13-16 years (60 ± 41 ppb) and 16-19 years (54 ± 31 ppb). The more rapid increase that occurs between the second and third age ranges is statistically highly significant (p = 0.001) and we attribute this phenomenon to the onset of puberty and the spurt in growth that occurs during this phase of development. There is no significant difference in mean breath isoprene between males and females for both the adult cohort and the younger cohort.

Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis.

HYPOTHESIS: Hydrogen cyanide (HCN) is emitted by Pseudomonas aeruginosa (PA) in vitro. We hypothesized that exhaled HCN could be measured using Selected Ion Flow Tube Mass Spectrometry (SIFT-MS) and that concentrations would be higher in children with cystic fibrosis (CF) and PA infection than in children with asthma. METHODS: Children aged 7-17 years with CF (n = 16) or asthma (n = 21) attending outpatient clinics provided breath samples between July and December 2007. HCN was measured using the SIFT-MS Profile 3 instrument. FeNO was measured with a Sievers NOA 280i analyzer. Baseline inter-group differences between HCN and FeNO concentrations were compared using the Mann-Whitney U test. Children were invited to re-attend fortnightly. Breath samples, spirometry, growth and clinical status were measured at each visit. RESULTS: There were significant baseline differences in exhaled HCN and FeNO concentrations between the two groups. Children with CF had higher median HCN concentrations than those with asthma: 13.5 parts per billion (ppb) (IQR 8.1-16.5) versus 2.0 ppb (IQR 0.0-4.8) (P < 0.001). Children with CF had lower median FeNO levels compared to children with asthma: 13.4 ppb (IQR 8.9-17.6) versus 57.9 ppb (IQR 34.0-85.7) (P < 0.001). Intra-subject variability was high and significant changes in HCN concentrations were not observed related to changes in lung function or clinical status. CONCLUSION: This study provides proof of principle that HCN is detectable in the breath of children with CF and is elevated compared to children with asthma. Further studies are required to capture data from acutely unwell children and more accurately delineate responses to treatment.